Champions Oncology, Inc. (NASDAQ: CSBR) – Q3 2026 Earnings
Champions Oncology, Inc. (NASDAQ: CSBR) – Q3 2026 Earnings
Press release and earnings call link
Section 1: Short Tear Sheeet
Champions Oncology is a translational oncology research company that sells preclinical oncology services to biopharma customers, using a large bank of patient-derived xenograft (PDX, tumor models grown from patient cancer samples) and related lab capabilities. Its main revenue driver today is study services, while management is trying to build two additional growth engines: a data licensing/platform business and Corellia, its discovery therapeutics subsidiary. The company appears to occupy a specialized niche rather than mass-market scale leadership, with its tumor bank and radiopharma capabilities positioned as differentiators. Financially, the business is in a transition phase: core study services are growing strongly, but total reported revenue and profitability comparisons are distorted by the absence of a large prior-year data deal and by elevated outsourced lab costs. Near-term management focus is on converting bookings to revenue, bringing radiolabeling work in-house to lift margins, monetizing the data platform more consistently, and potentially securing outside funding for Corellia.
Quarterly Results
Earnings Release Date: Mar. 12, 2026
Stock Price: $5.90
Market Cap: $81.9 million
Q3 2026 sales of $16.6 million vs $17.0 million in the prior year
Q3 2026 Non-GAAP Adjusted EPS of $0.04 vs $0.36 in the prior year
Q3 2026 GAAP Diluted EPS of $(0.02) vs $0.31 in the prior year
Quick Takeaway
Champions Oncology is in a growth-transition phase, focusing on scaling its core translational oncology services business while trying to turn its data platform and Corellia subsidiary into meaningful value drivers. The call contained real positives: record study revenue, continued positive adjusted EBITDA, better operating leverage, and emerging data monetization. But there are still concerns around quarterly volatility, gross margin compression, modest cash reserves, and uncertainty around Corellia funding. Execution on Q4 data revenue, margin recovery from in-sourcing, and proof that newer businesses can contribute without straining capital will be critical.
Press Release vs Call Transcript Comparison
The most important investor takeaway is that the press release is mostly a “defend the quarter” document, while the call is a “re-rate the model” document. The release explains why total revenue and margins looked worse. The call tries to convince investors that the current reported numbers understate the normalized earnings power of the services business and understate the future value of the data platform and Corellia.
Another important nuance is that the prior-year comparison was flattered by a $4.5 million data deal. That means year-over-year headline numbers are not especially useful without adjusting for revenue mix. On that adjusted view, core services growth of 32% is strong for a company of this size and suggests the underlying customer demand picture is healthier than the total revenue line alone suggests.
At the same time, investors should not ignore that deferred revenue fell from $15.4 million at April 30, 2025 to $10.0 million at January 31, 2026, and cash also declined. In a project-based business, these are not automatic danger signs, but they do mean future quarters need continued booking and billing conversion to keep the story intact.
Investor Underappreciation Signals
✅Service Revenue Quality — Core study services grew 32% year over year and nearly offset the absence of last year’s $4.5 million data deal, which suggests the core business is stronger than the flat-to-down headline revenue comparison implies; investors may be anchoring on total revenue decline instead of recognizing that underlying demand and execution in the core engine improved materially.
✅Margin Recovery from In-Housing — More than $2 million of quarterly cost of sales came from outsourced radiolabeling work, and management said gross margin would have been above 50% if that work had already been internalized; investors may be treating the 47% margin as structural when it appears at least partly transitional.
✅Operating Leverage Without Headcount Growth — Management said it delivered record service revenue without materially adding headcount, which hints that incremental revenue can scale through the model more efficiently than recent reported profitability suggests; investors may not appreciate this until margins visibly improve over several quarters.
✅Q4 Data Revenue Setup — The call disclosed a six-figure data deal closed in Q3 for Q4 recognition and incremental revenue expected from the earlier large data contract, which creates a near-term setup not obvious from the press release alone; investors may still think the data business is purely conceptual until that revenue actually lands in reported results.
✅Corellia Optionality — External funding for Corellia could reduce the EBITDA burden currently absorbed by Champions and either free capital for data growth or improve the bottom line, yet the market may be assigning little value because there is no firm timing and biotech funding remains slow; that perception could change quickly if management announces a financing or licensing event.
Section 2: Supplementary Information
Positive Insights
Negative Insights
Tariff Risk
There was no meaningful discussion of U.S. tariffs or trade policy in this transcript. Management did not mention tariff impacts on revenue, supply chain, profitability, pricing, market share, or innovation. They also did not discuss mitigation efforts such as supply chain relocation, renegotiation of contracts, or production shifts. From the transcript alone, tariff risk appears either immaterial to the current discussion or simply not addressed, so investors should not assume there is no exposure just because it was not mentioned.
Hot Stock Trends Analysis
Previous Earnings Call
Quarter-over-quarter comparison (Previous Analysis)
Q2 FY2026: Management focused on operational stabilization and execution, emphasizing improving biotech funding conditions, stronger conversion of booked studies, and early progress in strategic initiatives like the data platform and radiopharmaceutical services. The company highlighted revenue growth, improving margins, and disciplined capital management while positioning its investments as necessary to support future growth.Q3 FY2026: The narrative shifted toward demonstrating strategic progress and long-term value creation, with management highlighting record services revenue, early monetization of the data platform, and continued development of Corellia. The company framed itself as evolving into a multi-engine growth platform driven by services, data, and drug discovery, while acknowledging that the payoff from these investments is expected to materialize beginning in fiscal 2027.
Year-over-year comparison (Previous Analysis)
Q3 FY2025: Management framed the quarter as a transformational milestone, highlighted by record revenue and the company’s first major data licensing deal. The call focused on validating the strategic value of Champions’ deep tumor dataset and positioning the data platform as a potential high-margin growth engine alongside the core oncology services business.
Q3 FY2026: The narrative shifted toward execution and scaling, with management emphasizing record services revenue, early momentum in additional data deals, and continued investment in Corellia. Rather than celebrating a single breakthrough, the company now presents itself as a diversified platform built around services, data, and drug discovery, with the financial payoff expected to begin materializing in fiscal 2027 and beyond.